Emergencies of calcium homeostasis

Reviews in Endocrine and Metabolic Disorders

Volumn 4, Issue 2, 2003, Pages 167-175

  Body, Jean Jacques ^a   Bouillon, Roger ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Bisphosphonates; Endocrine emergency; Hypercalcemia; Hypocalcemia; Parathyroid hormone

Indexed keywords

CALCIUM CHLORIDE; CLODRONIC ACID; GLUCONATE CALCIUM; IBANDRONIC ACID; OSTEOPROTEGERIN; PAMIDRONIC ACID; ZOLEDRONIC ACID;

CALCIUM HOMEOSTASIS; CLINICAL FEATURE; FEVER; FLU LIKE SYNDROME; GRANULOMATOSIS; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; NEPHROTOXICITY; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT INDICATION; VEIN DISEASE; VITAMIN D INTOXICATION;

EID: 0038374778     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022994104070     Document Type: Review

References (46)

1. Van Cromphaut SJ, Dewerchin M, Hoenderop JGJ, Stockmans I, Van Herck E, Kato S, Bindels RJM, Collen D, Carmeliet P, Bouillon R, Carmeliet G. Duodenal calcium absorption in vitamin D receptor-knockout mice: Functional and molecular aspects. PNAS 2001;98:13324-13329.
2. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357.
3. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AHG, Rubens RD, for the International Bone and Cancer Study Group. Current use of bisphosphonates in oncology. J Clin Oncol 1998;16:3890-3899.
4. Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994;73:2223-2230.
5. de Wit S, Cleton FJ. Hypercalcemia in patients with breast cancer: A survival study. J Cancer Res Clin Oncol 1994;120:610-614.
6. Body JJ, Delmas PD. Urinary pyridinium crosslinks as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 1992;74:471-475.
7. Dumon JC, Wantier H, Mathieu F, Mantia M, Body JJ. Technical and clinical validation of a new immunoradiometric assay for human osteocalcin. Eur J Endocrinol 1996;135:231-237.
8. Nagai Y, Yamato H, Akaogi K, Hirose K, Ueyama Y, Ikeda K, Matsumoto T, Fujita T, Ogata E. Role of interleukin-6 in uncoupling of bone in vivo in a human squamous carcinoma coproducing parathyroid hormone-related peptide and interleukin-6. J Bone Miner Res 1998;13:664-672.
9. Nakayama K, Fukumoto S, Takeda S, Takeuchi Y, Ishikawa T, Miura M, Hata K, Hane M, Tamura Y, Tanaka Y, Kitaoka M, Obara T, Ogata E, Matsumoto T. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 1996;81:607-611.
10. Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, Moseley JM, Martin TJ. Parathyroid hormone-related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 1991;73:1309-1315.
11. Singer FR, Ritch PS, Lad TE, Ringenberg QS, Schiller JH, Recker RR, Ryzen E. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. Arch Intern Med 1991;151:471-476.
12. Kanis JA, McCloskey EV. Bisphosphonates in the treatment of multiple myeloma. In: Body JJ, ed. Tumor Bone Diseases and Osteoporosis in Cancer Patients. New York & Basel: Marcel Dekker Inc, 2000:457-481.
13. Hosking DJ, Gilson D. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. Q J Med 1984;53:359-368.
14. Ralston SH, Thiébaud D, Herrmann Z, Steinhauer EU, Thürlimann B, Walls J, Lichinitser MR, Rizzoli R, Hagberg H, Huss HJ, Tubiana-Hulin M, Body JJ. Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia. Br J Cancer 1997;75:295-300.
15. Body JJ. Current and future directions in medical therapy: Hypercalcemia. Cancer 2000;88:3054-3058.
16. Dumon JC, Magritte A, Body JJ. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone and Mineral 1991;15:257-266.
17. O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D, Kanis JA. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 1993;67:560-563.
18. Shah S, Hardy J, Rees E, Ling J, Gwilliam B, Davis C, Broadley K, A'Hern R. Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia? Br J Cancer 2002;86:1235-1237.
19. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995;72:1289-1293.
20. Walker P, Watanabe S, Lawlor P, Hanson J, Pereira J, Bruera E. Subcutaneous clodronate: A study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol 1997;8:915-916.
21. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30, 60, 90 mg doses. Am J Med 1993;95:297-304.
22. Body JJ, Dumon JC. Treatment of tumor-induced hypercalcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of the tumour type. Ann Oncol 1994;5:359-363.
23. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993;341:1611-1613.
24. Walls J, Ratcliffe WA, Howell A, Bundred NJ. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: The role of parathyroid hormone-related protein. Br J Cancer 1994;70:169-172.
25. Rizzoli R, Thiebaud D, Bundred N, Pecherstorfer M, Herrmann Z, Huss HJ, Ruckert F, Manegold C, Tubiana-Hulin M, Steinhauer EU, Degardin M, Thurlimann B, Clemens MR, Eghbali H, Body JJ. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 1999;84:3545-3550.
26. Body JJ, Louviaux I, Dumon JC. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Supportive Care in Cancer 2000;8:398-404.
27. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-751.
28. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thürlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiébaud D. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996;14:268-276.
29. Pecherstorfer M, Steinhauer E, Pawsey SD. Ibandronic acid is more effective than pamidronic in lowering serum calcium inpatients with severe hypercalcemia of malignancy (HCM) and has at least equal efficacy to pamidronate in HCM patients with lower baseline calcium levels. Results of a randomised open label, comparative study. Proceedings of ASCO 2001;20:385A.
30. Oleffe V, Dumon JC, Body JJ. Tumor-induced hypercalcemia in a patient with extensive soft tissue sarcoma: Effects of bisphosphonate therapy and surgery. J Surg Oncol 1996;63:125-129.
31. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14:1557-1561.
32. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HG, Yunus F, Bell R, Body JJ, Quebe-Fehling E, Seaman J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567.
33. Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: Novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol 1999;141:195-210.
34. Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Sarosi I, Lacey DL, Dunstan CR. Comparison of osteoprotegerin and pamidronate in a murine model of humoral hypercalcemia of malignancy. J Bone Miner Res 1999;14 (Suppl 1):S163.
35. Rosen LS, Gordon D, Antonio BS, Kaminski M, Howell A, Belch A, Mackey JA, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
36. Schmidli RS, Wilson I, Espiner EA, Richards AM, Donald RA. Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: Effect on clinical status. Clin Endocrinol 1990;32:293-300.
37. Jansson S, Tisell LE, Lindstedt G, Lundberg PA. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Surgery 1991;110:480-486.
38. Marcus R. Diagnosis and treatment of hyperparathyroidism. Rev Endocr Metab Disord 2000;1:247-252.
39. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001;16:113-119.
40. Grey A. Primary hyperparathyroidism: Medical management. Clin Rev in Bone and Mineral Metabolism 2002;1:35-42.
41. Selby PL, Davies M, Marks JS, Mawer EB. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin Endocrinol 1995;43:531-536.
42. Rizzoli R, Stoermann C, Ammann P, Bonjour JP. Hypercalcemia and hyperosteolysis in vitamin D intoxication: Effects of clodronate therapy. Bone 1994;15:193-198.
43. 3. Quaterly Journal of Medicine, new series LIII 1984;210:165-180.
44. Chesney RW, Hamstra AJ, DeLuca HF, Horowitz S, Gilbert EF, Hong R, Borcherding W. Elevated serum 1,25-dihydroxyvitamin D concentrations in the hypercalcemia of sarcoidosis: Correction by glucocorticoid therapy. J Pediatr 1981;98:919-922.
45. Kozeny GA, Barbato AL, Bansal VK, Vertuno LL, Hano JE. Hypercalcemia associated with silicone-induced granulomas. N Engl J Med 1984;311:1103-1105.
46. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am 1993;22:363-375.